1487 related articles for article (PubMed ID: 29609754)
1. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
Pirillo A; Catapano AL
Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
4. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
Pokrywka GS
Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibitors in the prevention of cardiovascular disease.
Latimer J; Batty JA; Neely RD; Kunadian V
J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
8. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
10. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
11. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
[TBL] [Abstract][Full Text] [Related]
12. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
[TBL] [Abstract][Full Text] [Related]
13. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
Turgeon RD; Pearson GJ
Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
16. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
17. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?].
Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M
Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302
[TBL] [Abstract][Full Text] [Related]
18. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
19. New Drugs for Lowering LDL-Cholesterol.
Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
